Trial
NCT03662074
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Wake Forest University Health Sciences
Collaborators
National Cancer Institute (NCI)
Condition
Small Cell Lung Carcinoma
Intervention
Gemcitabine
Why stopped
After interim analysis decided not to move forward with continuing the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-02